Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About TREX WIND-DOWN, INC.
Timber Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The company is headquartered in Warren, New Jersey and currently employs 9 full-time employees. The company went IPO on 2015-06-11. The firm is focused on the development and commercialization of treatments for orphan dermatologic diseases. The firm is also focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), including X-linked recessive CI (XLRI) and autosomal recessive CI (ARCI) and other sclerotic skin diseases. Its lead late-stage program is TMB-001. TMB-003 is its earliest stage program. TMB-001 is a topical formulation of isotretinoin using its patented IPEG delivery system, completed its Phase IIb clinical trial for the treatment of moderate to severe subtypes of CI. The earliest stage product in its pipeline is TMB-003, a formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist. The company is in preclinical development as a locally applied formulation for the treatment of sclerotic skin diseases.
Industry: Pharmaceutical Preparations Peers: Ampio Pharmaceuticals, Inc. cbdMD, Inc. PLx Pharma Winddown Corp. Eloxx Pharmaceuticals, Inc. Evofem Biosciences, Inc. JOHNSON & JOHNSON KALA BIO, Inc. OTONOMY, INC. TITAN PHARMACEUTICALS INC
